| Identification | Back Directory | [Name]
Nisoxetine | [CAS]
53179-07-0 | [Synonyms]
Nisoxetine
Compound 89218
Benzenepropanamine, γ-(2-methoxyphenoxy)-N-methyl-
[3-(2-Methoxy-phenoxy)-3-phenyl-propyl]-methyl-amine | [Molecular Formula]
C17H21NO2 | [MDL Number]
MFCD00865443 | [MOL File]
53179-07-0.mol | [Molecular Weight]
271.36 |
| Chemical Properties | Back Directory | [Boiling point ]
404.8±40.0 °C(Predicted) | [density ]
1.054±0.06 g/cm3(Predicted) | [form ]
Viscous Liquid | [pka]
10.16±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Antidepressant. | [Definition]
ChEBI: Nisoxetine is a secondary amino compound that is N-methyl-3-phenylpropan-1-amine substituted at position 3 by a 2-methoxyphenoxy group. It has a role as an antidepressant and an adrenergic uptake inhibitor. It is an aromatic ether and a secondary amino compound. | [General Description]
Nisoxetine is a SNERI and is an antidepressant. Most activityresides in the β-isomer. | [Clinical Use]
Nisoxetine was the initial phenoxyphenylpropylamine synthesized in the Lilly research laboratories
during the early 1970s from the rearrangement of an oxygen atom in diphenyhydramine, a
diphenylmethoxyethylamine, to a phenoxyphenylpropylamine. Nisoxetine was discovered to be a
potent and very selective SNRI, with little affinity for other receptors. It underwent clinical studies as an
alternative to Lilly's best-selling antidepressant, nortriptyline, but without the adverse effects associated with
the tricyclic secondary amines. It was never marketed, however, because of a greater interest in developing
its 4-trifluoromethyl analogue, fluoxetine, an SSRI. |
|
|